Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.

× No keyword cloud information.

13 in total

1. Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors: Yu Kawashima; Akio Oishi; Akitaka Tsujikawa; Kenji Yamashiro; Masahiro Miyake; Naoko Ueda-Arakawa; Munemitsu Yoshikawa; Ayako Takahashi; Nagahisa Yoshimura
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2014-11-13 Impact factor: 3.117

2. Volume and composition of reflux after intravitreal injection.

Authors: Frank L Brodie; Jason Ruggiero; Devon H Ghodasra; James Z Hui; Brian L VanderBeek; Alexander J Brucker
Journal: Retina Date: 2014-07 Impact factor: 4.256

Review 3. Short-term effect of aflibercept on visual acuity and central macular thickness in patients not responding to ranibizumab and bevacizumab.

Authors: Sandra Maksys; Sibylla Richter-Müksch; Birgit Weingessel; Pia Veronika Vécsei-Marlovits
Journal: Wien Klin Wochenschr Date: 2016-08-22 Impact factor: 1.704

4. Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes.

Authors: Meidong Zhu; Jamie K Chew; Geoffrey K Broadhead; Kehui Luo; Nichole Joachim; Thomas Hong; Adil Syed; Andrew A Chang
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2014-09-10 Impact factor: 3.117

5. Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy.

Authors: Taiichi Hikichi
Journal: BMC Ophthalmol Date: 2015-04-10 Impact factor: 2.209

Review 6. Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration.

Authors: Chandrakumar Balaratnasingam; Elona Dhrami-Gavazi; Jesse T McCann; Quraish Ghadiali; K Bailey Freund
Journal: Clin Ophthalmol Date: 2015-12-17

7. Treatment of polypoidal choroidal vasculopathy by photodynamic therapy, aflibercept and dexamethasone triple therapy.

Authors: Mary Ho; Donald C F Woo; Vesta C K Chan; Alvin L Young; Marten E Brelen
Journal: Sci Rep Date: 2016-11-16 Impact factor: 4.379

8. A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis.

Authors: Rishi P Singh; Sunil Srivastava; Justis P Ehlers; Rumneek Bedi; Andrew P Schachat; Peter K Kaiser
Journal: Br J Ophthalmol Date: 2014-06 Impact factor: 4.638

9. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).

Authors: Charles C Wykoff; David M Brown; Maria E Maldonado; Daniel E Croft
Journal: Br J Ophthalmol Date: 2014-02-11 Impact factor: 4.638

Review 10. Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept.

Authors: Alfredo García-Layana; Marta S Figueroa; Javier Araiz; José M Ruiz-Moreno; Francisco Gómez-Ulla; Luis Arias-Barquet; Nicholas Reiter
Journal: Drugs Aging Date: 2015-10 Impact factor: 3.923